ArticleJournal of fluorescence2025
Eco-friendly Nano-scale Bio-analytical Insights for Spectrofluorimetric Estimation of Fimasartan Using Integrated Approach of Enhanced Microwave-assisted Hantzsch Reaction and Multicolored Analytical Chemistry.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fourier-based chemometric resolution of the FOLFOX regimen through digital filtering with poly-metric sustainability assessment.Scientific reports · 2026Article
- Sustainable miniaturized smartphone-coupled TLC platform for innovative cleaning validation: application to tizanidine combinations under challenging concentration ratios.Scientific reports · 2026Article
- AQbD-driven RP-HPLC method for complete resolution of pantoprazole regioisomeric impurities with integrated multi-dimensional sustainability assessment.BMC chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study introduces an innovative spectrofluorimetric method for determining fimasartan, a pharmaceutical compound, at low concentrations in drug formulations and human blood samples. The method incorporates several key features that enhance its effectiveness and sustainability. It utilizes eco-friendly solvents (water and ethanol) and reduces analysis time, making it both cost-effective and environmentally friendly. The integration of Quality by Design (QbD) principles ensures consistent quality throughout the analytical process. The method employs a microwave-assisted Hantzsch reaction for derivatization, which modifies the compound for improved detection. To optimize critical variables, the Placket-Burman design, a statistical tool, was implemented. The method demonstrates high performance with linearity in the range of 50-250 ng/mL, a Limit of Detection (LOD) of 10 ng/mL, and a Limit of Quantification (LOQ) of 50 ng/mL. It achieves excellent accuracy, with 99.61-100.58% recovery in pharmaceutical formulations and 91.67-94.94% in human plasma. The rapid analysis time of 30 s for derivatization further enhances its efficiency. Mass spectrometry confirmation verified the formation of a fluorescent Mannich base product. Notably, this method outperforms existing LC-MS and HPLC techniques based on RGB12, AGREE, and modified-GAPI assessments, demonstrating superior environmental performance. By successfully combining analytical quality, environmental sustainability, and cost-effectiveness, this new spectrofluorimetric method presents a valuable tool for researchers and pharmaceutical professionals in the analysis of fimasartan. Its ability to provide accurate measurements at very small nano-scale concentrations while maintaining eco-friendly practices makes it a significant advancement in pharmaceutical analysis techniques.
Indexed as
Identifiers
40818015What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.